#China #Shanghai #Senaparib #IMPACT Therapeutics #Pharmanovia

IMPACT Therapeutics and Pharmanovia Join Forces

In a pivotal move for cancer treatment accessibility, IMPACT Therapeutics has officially entered into an exclusive licensing agreement with Pharmanovia regarding Senaparib, a novel cancer therapy. This collaboration empowers Pharmanovia with exclusive rights to manufacture, develop, and market Senaparib in Europe, the Middle East, North Africa, Australia, and New Zealand.

The Significance of the Agreement

The implications of this partnership are far-reaching. With Pharmanovia's established infrastructure and market expertise, the distribution of Senaparib could expand rapidly across 66 countries. The deal is not just about market penetration; it reflects a commitment to providing patients with new, effective treatment options for high-grade serous ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.

As part of the agreement, IMPACT Therapeutics stands to gain initial payments, along with regulatory and commercial milestone payments totaling up to €423.5 million. This represents a significant financial uplift for IMPACT, which is crucial for its ongoing research and development efforts in precision cancer therapies. Additionally, the company is eligible for tiered royalties on product sales, further incentivizing the successful marketing of Senaparib.

Regulatory Milestones and Future Outlook

The European Medicines Agency (EMA) has already accepted the marketing authorization application for Senaparib, indicating strong regulatory support for the therapy in the region. The anticipated approval in the latter half of 2026 marks a crucial step toward making innovative treatments available to patients who are in dire need of effective options.

This partnership stands out as IMPACT's first foray into international markets outside China, significantly broadening its footprint while allowing the company to leverage Pharmanovia's established networks and operational capabilities. The strategic alliance aims to expedite the commercial journey of Senaparib, ensuring that patients in these key regions gain timely access to a therapy that has shown promise in clinical settings.

Understanding Senaparib

Senaparib (IMP4297) is a potent PARP1/2 inhibitor, independently developed by IMPACT Therapeutics. It differentiates itself through its unique molecular structure that achieves a high degree of target selectivity and safety. This therapy has already seen successful FDA approval in China, where it has been adopted as a first-line maintenance treatment for advanced ovarian cancer patients who have responded to platinum-based chemotherapy.

The anticipated expansion into Europe and other regions not only enhances IMPACT's brand recognition on a global platform but also complements its overarching strategy of becoming a primary player in the worldwide oncology market. As IMPACT Therapeutics continues to innovate, the partnership with Pharmanovia embodies a shared vision of improving patient outcomes and addressing unmet medical needs.

About IMPACT Therapeutics

Founded in 2009, IMPACT Therapeutics is a biotechnology company dedicated to advancing synthetic lethality-based precision therapies for cancer treatment. With its successful listing on the Hong Kong Stock Exchange, the company is one of the few with commercial-stage PARP inhibitors and continues to push the boundaries of oncological research.

About Pharmanovia

Pharmanovia specializes in innovative medicines and established health brands, combining scientific, medical, and commercial expertise to bring vital medications to patients. This collaboration with IMPACT Therapeutics underscores their shared mission to search for better health solutions and improve future patient outcomes.

Through this strategic partnership, both companies aim to revolutionize cancer care, making strides towards a future where treatments are not only available but also accessible to those who need them most.